Asterixis, often described as "negative myoclonus," is a distinctive neurological finding in corticobasal syndrome (CBS) that reflects cortical hyperexcitability and impaired motor inhibition. Unlike positive myoclonus (involuntary muscle contractions), asterixis manifests as brief, involuntary lapses in muscle tone when maintaining a posture, resulting in sudden jerky movements or "flapping" motions.
- Brief muscle tone lapses: Sudden, brief losses of postural tone lasting 50-200 milliseconds
- Postural lapses: Most prominent when maintaining outstretched arm positions
- Jerky movements: irregular, arrhythmic "flapping" motions of the hands or fingers
- Bilateral asymmetry: Often more pronounced on the more affected side in CBS
- Task-specific: Exacerbated by sustained posture holding, fine motor tasks, or voluntary movement
Asterixis is frequently confused with myoclonus but has distinct electrophysiological features:
| Feature |
Asterixis (Negative Myoclonus) |
Positive Myoclonus |
| Movement direction |
Downward "drop" |
Upward jerk |
| EMG activity |
Silent gap |
Burst of activity |
| EEG correlate |
Slow wave |
Spike |
| Origin |
Cortical inhibition failure |
Cortical excitation |
- Cortical hyperexcitability: Reduced intracortical inhibition allows inappropriate tone withdrawal
- Failed motor inhibition: Abnormal gating in the motor cortex leads to unwanted inhibition
- Thalamic modulation: The ventral lateral thalamic nucleus contributes to the phenomenon
- Basal ganglia dysfunction: Loss of normal inhibitory control via the direct/indirect pathways
flowchart TD
A["Motor Cortex<br/>Hyperexcitability"] --> B["Imbalance: Excitation > Inhibition"]
B --> C["Inappropriate Cortical Output"]
C --> D["Brief Muscle Tone Withdrawal"]
D --> E["Postural Lapse<br/>Asterixis"]
A --> F["Thalamic<br/>Dysfunction"]
F --> C
A --> G["Basal Ganglia<br/>Circuit Dysfunction"]
G --> C
style A fill:#e1f5fe,stroke:#333
style E fill:#ffcdd2,stroke:#333
- Asterixis vs. Tremor: Tremor is rhythmic; asterixis is irregular
- Asterixis vs. Myoclonus: Asterixis shows EMG "silent gap"; myoclonus shows EMG burst
- Asterixis vs. Chorea: Chorea flows smoothly; asterixis is discrete and posture-bound
Asterixis is common in CBS but varies based on the underlying pathology:
- Tau-predominant CBS: 30-50% of patients
- CBS with AD pathology: 20-35% of patients
- CBS with Lewy body pathology: 15-25% of patients
The presence of asterixis often correlates with:
- More severe cortical dysfunction
- Presence of myoclonus
- Higher cortical hyperexcitability on neurophysiological testing
- Silent gap: 50-200ms pause in EMG activity during posture maintenance
- Bilateral recording: Often shows asynchronous lapses between muscles
- Post-reaction: Brief burst following the silent gap as muscle re-engages
- Cortical origin: Movement-related cortical potentials precede asterixis
- Corticomyographic silence: No preceding EEG event, reflecting pure "release" phenomenon
- Giant sensory evoked potentials: Often present, indicating cortical hyperexcitability
SSEPs are frequently abnormal in CBS with asterixis:
- N20-P39 amplitude: Significantly increased (> 2x normal)
- Central conduction time: Often prolonged
- Diagnostic value: Helps distinguish cortical (with asterixis) from subcortical movement disorders
Asterixis helps differentiate CBS from other parkinsonian syndromes:
- CBS: Common (30-50%), reflects cortical pathology
- PSP: Rare (< 10%), vertical gaze palsy more characteristic
- PD: Uncommon (< 5%), rest tremor more characteristic
- MSA: Very rare (< 5%), autonomic failure dominates
- Asterixis correlates with more severe cortical involvement
- Associated with faster disease progression
- Predicts poorer response to dopaminergic therapy
- Often co-occurs with other cortical signs (apraxia, alien limb)
- Interferes with fine motor tasks (writing, eating, buttoning)
- Causes fatigue with sustained postures
- Contributes to fall risk when legs are affected
- Embarrassment and social withdrawal
| Treatment |
Mechanism |
Evidence |
Notes |
| Clonazepam |
GABA-A modulation |
Moderate |
First-line, start low dose |
| Valproic acid |
GABA enhancement |
Moderate |
Monitor liver function |
| Levetiracetam |
SV2A modulation |
Limited |
Often used off-label |
| Piracetam |
Unknown |
Limited |
May help some patients |
| 5-HTP |
Serotonin precursor |
Anecdotal |
Monitor for serotonin syndrome |
- Postural adaptations: Use arm rests, adaptive equipment
- Lifestyle modifications: Avoid sustained postures, frequent position changes
- Occupational therapy: Adaptive techniques for daily activities
- Assistive devices: Weighted utensils, writing aids
Asterixis in CBS often responds less dramatically to treatment than cortical myoclonus. Response depends on:
- Underlying pathology (tau vs. synuclein)
- Severity of cortical dysfunction
- Co-existing myoclonus
- Metabolic encephalopathy: Asterixis is classic in hepatic encephalopathy
- Uremia: Common in advanced kidney disease
- Medications: Anticonvulsants, benzodiazepine withdrawal
- Thalamic lesions: Vascular, tumor, or demyelination
- Degenerative diseases: CBS most common neurodegenerative cause
| Condition |
Associated Features |
| CBS |
Asymmetric presentation, apraxia, cortical sensory loss |
| Hepatic encephalopathy |
Jaundice, asterixis with eyes closed |
| Uremia |
Edema, altered mental status |
| Thalamic stroke |
Contralateral sensory loss |
- Quantification methods: EMG-based objective measurement
- Therapeutic targets: Cortical inhibition restoration
- Biomarker correlation: Relationship to neurophysiological markers
- Treatment trials: Disease-modifying approaches for CBS
- Clinical features of corticobasal syndrome
- Myoclonus and asterixis in degenerative diseases
- Cortical hyperexcitability in corticobasal degeneration
- Giant SSEP in corticobasal syndrome
- Electrophysiological differentiation of myoclonus and asterixis